What’s going on with convalescent plasma?

August 24, 2020
Another busy August Monday with news on an FDA emergency use authorization and biofuels plus the start of the virtual RNC. As a reminder, today’s also the day that President Trump said he would publish his drug pricing executive order; we’ll be watching this closely…
BIO

Another busy August Monday with news on an FDA emergency use authorization and biofuels plus the start of the virtual RNC. As a reminder, today’s also the day that President Trump said he would publish his drug pricing executive order; we’ll be watching this closely. Here are just about 1,000 words, 5 minutes.

What's going on with convalescent plasma?

To catch you up, here’s a recap of what happened at the U.S. Food and Drug Administration (FDA) over the weekend and what the country’s top health officials are saying about convalescent plasma. 

First, what is convalescent plasma? In simplest terms, convalescent plasma is the part of the blood that contains COVID-19 antibodies. Doctors think they can take plasma donated by people who have recovered from COVID-19, inject it into other patients, and transfer some kind of immunity or help them fight the virus until they create their own antibodies or get a vaccine. (STAT News has an explainer.)

Last week, the prospects for emergency authorization of convalescent plasma for the treatment of COVID-19 dimmed when leading scientists at the NIH expressed concerns about its utility, as The New York Times reported.

Yesterday, however, the FDA issued the emergency authorization, on the grounds that it “may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product,” per the agency’s press release.

Meanwhile, President Trump had implied that any resistance to approval of COVID-19 vaccines or therapies could be politically motivated. We at BIO stand strongly against any non-scientific pressure on the process.

What they’re saying: “I am committed to releasing safe and potentially helpful treatments for COVID-19 as quickly as possible in order to save lives. We’re encouraged by the early promising data that we’ve seen about convalescent plasma. The data from studies conducted this year shows that plasma from patients who’ve recovered from COVID-19 has the potential to help treat those who are suffering from the effects of getting this terrible virus,” said FDA Commissioner Dr. Stephen Hahn. “At the same time, we will continue to work with researchers to continue randomized clinical trials to study the safety and effectiveness of convalescent plasma in treating patients infected with the novel coronavirus.”

Former FDA Commissioners Dr. Scott Gottlieb and Dr. Mark McClellan also weighed in, writing an op-ed in The Wall Street Journal in support. Dr. Gottlieb tweeted, “The FDA professional staff supported this. It’s their decision.” 

Dr. Michelle’s Diagnosis: BIO stands firmly on the side of science and scientists across America working hard to bring an end to the COVID-19 pandemic. There is no silver bullet to ending COVID-19, and convalescent plasma is just one piece of the complex puzzle. We need to continue to research a wide variety of therapeutics and vaccines, including plasma. Furthermore, we need to ensure the scientists at FDA are allowed to do their work, independently, and that FDA officials’ decisions are allowed to stand. The science, not politics, should drive these decisions. – BIO President and CEO Dr. Michelle McMurry-Heath


More Health Care News: 

Biopharma Dive: Coronavirus vaccine Pfizer, BioNTech chose for late-stage testing appears safer than first
“The data disclosed Thursday support their decision, showing the selected vaccine, dubbed BNT162b2, in particular led to fewer cases of fever than the first version.” 

Reuters: Johnson & Johnson to test coronavirus vaccine in 60,000 volunteers
“The phase 3 trial will likely lock off in late September, with the first vaccines available for use by early 2021.” 

The Wall Street Journal: Antibody drugs advancing to fill COVID-19 treatment gap
“Companies including Regeneron and Eli Lilly are testing drugs to help protect people infected with the virus from developing serious cases.”

Dallas Morning News (Opinion): Global pharmaceutical models would destroy U.S. medical innovation
“The companies who would be hurt the most by this proposed move would be small biotech businesses,” said Tom Kowalski, Chief Executive Officer of the Texas Healthcare and Bioscience Institute.

 
Twitter
 
LinkedIn
 
Facebook
 

Gevo’s renewable biofuel takes off

BIO member Gevo Inc. just inked a deal—it’s largest to date—to supply renewable, low-carbon gas and sustainable aviation fuel (SAF) to one of the world’s largest physical commodities trading companies. Here’s what it means for the biofuels industry and for the world.

Gevo, Inc. is commercializing gasoline and SAF made from feedstocks that perform “as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions,” says the company.

Gevo “integrates sustainable agriculture and biorefining” throughout the supply chain. “For every gallon of low-carbon premium gasoline or SAF produced, Gevo produces about ten pounds of protein for the food chain, delivering substantially all of the nutritional value of corn to the food chain. The farmers who supply Gevo on average are capturing carbon, building up their soil with regenerative agriculture techniques.”

Starting in 2023, Trafigura will take delivery of 25MPGY of renewable hydrocarbons, the majority of which will be “low-carbon premium gasoline” as well as sustainable aviation fuel.

What they’re saying: “Gevo’s renewable, very high-octane gasoline and SAF are a perfect fit with Trafigura’s existing fuels business and will allow them to integrate these low-carbon options seamlessly into their supply chains. We expect that our low-carbon fuels will enable certain of Trafigura’s customers to substantially lower their carbon footprint,” said Patrick Gruber, CEO of Gevo.

Why it matters: This is not only good news for our member company—it’s also good news for human health. As we wrote last week, air pollution is perhaps the greatest risk to human health, and it increases the risk of serious illness and death from COVID-19. We’re excited to see Gevo’s innovative fuels taking off with this deal. Now, policy needs to catch up with low-carbon fuel standards to support the development and use of biofuels and clean energy jobs.

Learn more about Gevo and SAF in this episode of the I AM BIO Podcast.

Learn more about the future of sustainable fuels.


More Agriculture and Environment News:

LanzaTech: CarbonSmart™ products hit the stores in Switzerland
"Switzerland’s largest retail company, Migros, and its subsidiary, Mibelle Group, have launched a new range of cleaning products, containing LanzaTech ethanol made from recycled pollution."

 
Twitter
 
LinkedIn
 
Facebook
 
BIO Beltway Report
GoodDayBIO
 
 

President Trump’s Monday: On Day 1 of the virtual Republican National Convention, he’s heading to North Carolina to visit Flavor First Growers and Packers and give remarks on a USDA program to give food boxes to families. Meanwhile, White House counselor Kellyanne Conway announced she’s stepping down

What’s Happening on Capitol Hill: The House Oversight and Reform Committee is holding a hearing on the U.S. Postal Service and the delivery of mail, medicines, and mail-in ballots. The RNC begins today with Sen. Tim Scott (R-SC) and former UN Ambassador Nikki Haley headlining; here’s the full speaker schedule for the week.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook